Episode 48: Efficacy Endpoints in Oncology Clinical Trials

In this QCast episode, Jullia and Tom discuss efficacy endpoints in oncology clinical trials and why endpoint choice shapes how treatment benefit is assessed. They look at overall survival, progression-free survival, objective response rate, disease-free survival, event-free survival, symptom endpoints, and quality-of-life measures.Key TakeawaysOverall survival remains one of the clearest measures of patient benefit, but it can require longer, larger trials and may be affected by treatments given after the study therapy.Progression-free survival and objective response rate can show treatment activity earlier, but they answer different questions from overall survival.Scan timing, missed assessments, censoring decisions, symptom questionnaires, and quality-of-life completion rates can all affect endpoint interpretation.🔗 Learn More & Get Support: Visit quanticate.com to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast.🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode.About QuanticateFounded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in:Clinical Data Capture & ManagementBiostatistics & Statistical ConsultancyStatistical Programming & PK/PD AnalysisMedical Writing & PharmacovigilanceRegulatory & Submission SupportAI & AutomationPost-Marketing Safety & Real-World DataQuanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.